MedTrace Logo

Cmate Blood Glucose Analyzer: Clinical Comparison Study of Fasting Blood Glucose Levels in the Morning

NCT07088497 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-01-26

No results posted yet for this study

Summary

As of February 2024, there are 529 million people worldwide living with diabetes. The number of diabetes patients continues to rise annually, and there is also a trend toward younger patients. Blood glucose management is crucial for prediabetes and diabetes patients. Effectively controlling blood glucose levels can reduce the risk of complications such as vascular complications, retinopathy, cardiovascular disease, and kidney disease. Traditionally, blood glucose monitoring in home settings has primarily relied on fingerstick whole blood samples combined with a blood glucose meter. However, this method poses risks associated with the disposal of used lancets and test strips, and the discomfort caused by the blood draw process can also lead to psychological stress for users. To enhance users' willingness to monitor blood glucose regularly and reduce environmental pollution from waste, the non-invasive blood glucose measurement system applied in this study is a non-invasive monitoring technology that is not a medical device and has not yet been marketed. It is currently undergoing the application process for FDA medical device certification in the United States. This trial will collect fasting venous plasma glucose levels, HbA1c, fingerstick whole blood glucose levels, and non-invasive glucose levels from patients in the morning. The primary analysis indicator is the correlation analysis between venous plasma glucose levels and non-invasive glucose levels.

Conditions

Interventions

BEHAVIORAL

dietary control

Subjects are required to have dinner at a specific time on the night before the test and to remain fasting on the next day until the test.

Sponsors & Collaborators

  • Taipei Medical University

    collaborator OTHER

  • Taipei Medical University Shuang Ho Hospital

    collaborator OTHER

  • Revlis Biotech Company Limited

    lead INDUSTRY

Principal Investigators

  • Ju-Chi Liu, Doctor · Taipei Medical University Shuang Ho Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-21
Primary Completion
2025-09-30
Completion
2025-10-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07088497 on ClinicalTrials.gov